Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides
CA 2443372 C · Owner: Vazquez Lopez, Ana Maria · Inventors: Alfonso Fernandez, Mauro A.; Perez Gonzalez, Alexis; Fernandez Molina, Luis Enrique
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the field of immunology and specifically to immunotherapeutic combinations that are used to impede the growth of tumour cells and/or to eliminate said cells. The present invention can be used to observe a therapeutic antitumour effect by combining idiotypic vaccines having an antiganglioside antibody (Ab1) as the active principle thereof with idiotypic vaccines, the active principle of which is an anti-idiotype antibody obtained against an antiganglioside antibody (Ab2) or with vaccines, the , active principle of which is one or more gangliosides. The invention relates to combinations of said vaccines which produce a synergism of the antitumour effect which …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 8, 2002 and granted May 28, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 8, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 8, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.